Terms: = Prostate cancer AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76 AND Treatment
14551 results:
1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract] [Full Text] [Related]
2. Role of N
Pan J; Tong F; Ren N; Ren L; Yang Y; Gao F; Xu Q
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38757383
[TBL] [Abstract] [Full Text] [Related]
3. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed prostate cancer.
Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
[TBL] [Abstract] [Full Text] [Related]
4. First in vitro measurement of VHEE relative biological effectiveness (RBE) in lung and prostate cancer cells using the ARES linac at DESY.
Wanstall HC; Burkart F; Dinter H; Kellermeier M; Kuropka W; Mayet F; Vinatier T; Santina E; Chadwick AL; Merchant MJ; Henthorn NT; Köpke M; Stacey B; Jaster-Merz S; Jones RM
Sci Rep; 2024 May; 14(1):10957. PubMed ID: 38740830
[TBL] [Abstract] [Full Text] [Related]
5. Projected estimates of cancer in Canada in 2024.
Brenner DR; Gillis J; Demers AA; Ellison LF; Billette JM; Zhang SX; Liu JL; Woods RR; Finley C; Fitzgerald N; Saint-Jacques N; Shack L; Turner D;
CMAJ; 2024 May; 196(18):E615-E623. PubMed ID: 38740416
[TBL] [Abstract] [Full Text] [Related]
6. Anorectal function and symptoms 6 months after robot-assisted laparoscopic radical prostatectomy: a single-center study.
Psarias T; Walter S; Holmbom M; Khayoun Issa I; Abdul-Sattar Aljabery F; Hallböök O
Scand J Urol; 2024 May; 59():104-108. PubMed ID: 38738961
[TBL] [Abstract] [Full Text] [Related]
7. treatment Related Acute Toxicities Between treatment with 3D-CRT and IMRT in Localised prostate cancer.
Hanif S; Osmani AH; Mallick J
J Coll Physicians Surg Pak; 2024 May; 34(5):573-577. PubMed ID: 38720219
[TBL] [Abstract] [Full Text] [Related]
8. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
Leclercq L; Bastide C; Lechevallier E; Walz J; Charvet AL; Gondran-Tellier B; Campagna J; Savoie PH; Long-Depaquit T; Daniel L; Rossi D; Pignot G; Baboudjian M
Fr J Urol; 2024 Mar; 34(2):102571. PubMed ID: 38717459
[TBL] [Abstract] [Full Text] [Related]
9. Quercetin exerts anti-tumor immune mechanism by regulating IL-6/JAK2/STAT3 signaling pathway to deplete Treg cells.
Liao Y; Xie X; Zhang C; Zhong H; Shan L; Yu P; Xu L
Toxicon; 2024 May; 243():107747. PubMed ID: 38714236
[TBL] [Abstract] [Full Text] [Related]
10. Impact of COVID-19 on the time to counseling and treatment of prostate cancer.
Filipas DK; Pose RM; Marks P; Tennstedt P; Beyer B; Tilki D; Isbarn H; Maurer T; Ludwig TA; Heinzer H; Steuber T
Aging Male; 2024 Dec; 27(1):2347465. PubMed ID: 38712892
[TBL] [Abstract] [Full Text] [Related]
11. Survival benefit of radical prostatectomy in patients with advanced TURP-diagnosed prostate cancer: a population-based real-world study.
Lin D; Lin L; Ye L; Li T; Wei Y; Li L
BMC Surg; 2024 May; 24(1):134. PubMed ID: 38702689
[TBL] [Abstract] [Full Text] [Related]
12. On the necessity of specialized knowledge-based models for SBRT prostate treatments plans.
Scaggion A; Cavinato S; Dusi F; El Khouzai B; Guida F; Paronetto C; Rossato MA; Sapignoli S; Scott ASA; Sepulcri M; Paiusco M
Phys Med; 2024 May; 121():103364. PubMed ID: 38701626
[TBL] [Abstract] [Full Text] [Related]
13. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
[TBL] [Abstract] [Full Text] [Related]
14. treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
Mathew Thomas V; Jo Y; Tripathi N; Roy S; Chigarira B; Narang A; Gebrael G; Hage Chehade C; Sayegh N; Galarza Fortuna G; Ji R; Campbell P; Li H; Agarwal N; Gupta S; Swami U
JAMA Netw Open; 2024 May; 7(5):e249417. PubMed ID: 38696168
[TBL] [Abstract] [Full Text] [Related]
15. prostate size ≥ 100 g and its association with long-term outcomes of Retzius-sparing robot-assisted radical prostatectomy.
Maltzman O; Tappero S; Caviglia A; Palagonia E; Buratto C; Chierigo F; Cellini V; Olivero A; Barbieri M; Secco S; Bocciardi AM; Galfano A; Dell'Oglio P
World J Urol; 2024 May; 42(1):283. PubMed ID: 38695988
[TBL] [Abstract] [Full Text] [Related]
16. Plant-Based Diets and Disease Progression in Men With prostate cancer.
Liu VN; Van Blarigan EL; Zhang L; Graff RE; Loeb S; Langlais CS; Cowan JE; Carroll PR; Chan JM; Kenfield SA
JAMA Netw Open; 2024 May; 7(5):e249053. PubMed ID: 38691361
[TBL] [Abstract] [Full Text] [Related]
17. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
[TBL] [Abstract] [Full Text] [Related]
18. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of treatment Response.
Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
[TBL] [Abstract] [Full Text] [Related]
19. Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer.
Thomsen FF; Garmo H; Egevad L; Stattin P; Brasso K
Scand J Urol; 2024 Apr; 59():76-83. PubMed ID: 38682731
[TBL] [Abstract] [Full Text] [Related]
20. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
[Next]
